Home › Multiple Myeloma › New Jersey
Multiple Myeloma clinical trials in New Jersey
37 studies for Multiple Myeloma are looking for participants at sites in New Jersey.
Cities in New Jersey
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Hackensack University Medical Center, Hackensack
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05201781A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Astera Cancer Care, East Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05552222Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
- Hackensack University Medical Center, Hackensack
RecruitingObservational study
Ages 10 and older · All sexes · Updated Nov 3, 2026 · NCT06323447A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07099391A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0363, Ridgewood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT05519085Mosaic Trial for Stem Cell Transplant Recipients
- Hackensack Meridian Health, Nutley
Recruiting
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06960993A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- MSK Basking Ridge, Basking Ridge
- MSK Monmouth, Middletown
- MSK Bergen, Montvale
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT05623020A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04973605A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05651932A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07681596Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Hackensack Meridian Health, Hackensack
- Carol G Simon Cancer Center, Morristown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07105059A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent only), Middletown
- Memorial Sloan Kettering Bergen (Consent Only), Montvale
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07249528Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06297226Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06976476A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
Recruiting
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06055894A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 1, 2026 · NCT06679829A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Astera Cancer Care, East Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- John Theurer Cancer Center, Hackensack
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT04661137Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
- Hackensack Meridian Health - John Theurer Cancer Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT03909412A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06988488A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07075185A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- MSK Basking Ridge, Basking Ridge
- MSK Monmouth, Middletown
- MSK Bergen, Montvale
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT05020236Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Jefferson Cherry Hill Hospital, Cherry Hill
- Sidney Kimmel Cancer Center Washington Township, Sewell
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, East Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06121843A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT06083922A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 16, 2026 · NCT07454382Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
- Rutgers Cancer Institute of New Jersey, New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated May 29, 2026 · NCT04211259Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Rutgers Cancer Institute of New Jersey /ID# 266833, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 12, 2026 · NCT06896916A Dietary Study for People With Multiple Myeloma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Recruiting
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT07226609A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Hackensack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06679101A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Atlantic Health, Morristown
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 4, 2026 · NCT06066346Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Jan 23, 2026 · NCT00582621CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Hackensack Meridian John Theurer Cancer Center, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- John Theurer Cancer Center at Hackensack UMC, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 5, 2025 · NCT05372354From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.